News Quantified


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

iBio (IBIO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $5.00 price target on the stock.

iBio Details Generative AI Antigen Platform to Speed GPCR Antibody Discovery and Close “Trust Gap” [Yahoo! Finance]

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

iBio Touts Bispecific Antibody Strategy for PH-HFpEF, Eyes Development Candidate in Q3 [Yahoo! Finance]

iBio (IBIO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $5.00 price target on the stock.

Form 8-K iBio, Inc. For: Apr 08

Form 4 iBio, Inc. For: Mar 26 Filed by: Banjak Marc

Form 4 iBio, Inc. For: Mar 19 Filed by: Duran Felipe

Form 4 iBio, Inc. For: Mar 19 Filed by: Brenner Martin

Form 8-K iBio, Inc. For: Mar 09

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}